ANTIVIRAL COMPOUNDS AND PREPARATIONS EFFECTIVE AGAINST BOVINE VIRAL DIARRHEA

Cover Page


Cite item

Full Text

Abstract

Bovine viral diarrhea virus (BVDV) belongs to the genus Pestivirus, family Flaviviridae. It causes various clinical forms of infection leading to significant economic losses in beef and dairy industry worldwide. Furthermore, the virus is a contaminant of biological preparations (bovine fetal serum, continuous cell cultures, vaccines for human and veterinary medicine, interferons, trypsin, biotechnological preparations, embryos, stem cells, etc.). It is used as a test object when developing methods of decontamination. In some countries, a tool for monitoring the infection caused by the virus is vaccination based on the use of live and inactivated vaccines with varying efficiency. The antiviral compounds are a potential means of control in case of insufficient efficacy of vaccines. Their advantage for BVDV control is the ability to provide immediate protection for animals at risk in the case of an outbreak of the disease. This review summarizes the current state of knowledge about antiviral compounds against BVDV. It was noted that due to the use of advanced biomedical technologies there is a tendency to search for drugs that might be effective for antiviral therapy of BVDV, as indicated by numerous studies of new compounds and the antiviral efficacy of known drugs used in medical practice. In addition to the well-known antiviral targets for the virus, such as the RdRp, IMPDH, NS3, new targets were discovered, such as protein p7. Its mechanism of action remains to be explored. It can be concluded that there is a great potential for BVDV control through the use of antiviral drugs which has not yet implemented. The biggest obstacle for commercial implementation of identified compounds is the lack of demonstration of their efficacy in vivo. Further studies should be performed to develop a method for administering effective drugs to groups of animals.

About the authors

T. I. Glotova

Siberian Federal Scientific Centre of Agro-Biotechnologies

Author for correspondence.
Email: t-glotova@mail.ru
Россия

A. A. Nikonova

Siberian Federal Scientific Centre of Agro-Biotechnologies

Email: noemail@neicon.ru
Россия

A. G. Glotov

Siberian Federal Scientific Centre of Agro-Biotechnologies

Email: noemail@neicon.ru
Россия

References

  1. King A.M.Q., Adams M.J., Carstens E.B., Lefkowitz E.J., eds. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press; 2011.
  2. Giammarioli M., Ceglie L., Rossi E., Bazzucchi M., Casciari C., Petrini S. et al. Increased genetic diversity of BVDV-1: recent findings and implications thereof. Virus Genes. 2015; 50(1): 147-51.
  3. Factor C., Yus E., Eiras C., Sanjuan M.L., Cerviño M., Arnaiz I. et al. Genetic diversity of bovine viral diarrhea viruses from the Galicia region of Spain. Vet. Rec. Open. 2016, 3(1): e000196.
  4. Deng M., Ji S., Fei W., Raza S., He C., Chen Y. et al. Prevalence study and genetic typing of bovine viral diarrhea virus (BVDV) in four bovine species in China. PLoS ONE. 10(4): e0121718.
  5. Hessman B.E., Sjeklocha D.B., Fulton R.W., Ridpath J.F., Johnson B.J., McElroy D.R. Acute bovine viral diarrhea associated with extensive mucosal lesions, high morbidity, and mortality in a commercial feedlot. J. Vet. Diagn. Invest. 2012; 24(2): 397-4.
  6. Глотов А.Г., Глотова Т.И., Семенова О.В., Котенева С.В., Никонова А.А. Индикаторы циркуляции вируса вирусной диареи (болезни слизистых оболочек) крупного рогатого скота на молочных комплексах в условиях Сибири. Сельскохозяйственная биология. 2016; 51(4): 483-90
  7. Moennig V., Becher P. Pestivirus control programs: how far have we come and where are we going? Anim. Health Res. Rev. 2015; 16(1): 83-7.
  8. Kalaycioglu A.T. Bovine viral diarrhoea virus (BVDV) diversity and vaccination. A review. Vet. Q. 2007; 29(2): 60-7.
  9. Pinheiro de Oliveira T.F., Fonseca A.A. Jr, Camargos M.F., de Oliveira A.M., Pinto Cottorello A.C., Souza Ados R. et al. Detection of contaminants in cell cultures, sera and trypsin. Biologicals. 2013; 41(6): 1-8.
  10. Buckwold V.E., Beer B.E., Donis R.O. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res. 2003; 60(1): 1-15.
  11. Урываев Л.В., Ионова К.С., Дедова А.В., Дедова Л.В., Селиванова Т.К., Прасюк Н.А. и др. Анализ контаминации культур пестивирусом BVDV и микоплазмами. Вопросы вирусологии. 2012; (5): 15-21
  12. Uryvaev A.V., Dedova L.V., Dedova K.S., Ionova K.S., Parasjuk N.A., Selivanova T.K. et al. Contamination of cell cultures with bovine viral diarrhea virus (BVDV). Bull. Exp. Biol. Med. 2012; 153(1): 77-81.
  13. Menéndez-Arias L., Gago F. Antiviral agents: structural basis of action and rational design. Subcell. Biochem. 2013; 68: 599-30.
  14. Newcomer B.W., Givens M.D. Approved and experimental countermeasures against pestiviral diseases: Bovine viral diarrhea, classical swine fever and border disease. Antiviral Res. 2013; 100(1): 133-50.
  15. Givens M.D., Dykstra C.C., Brock K.V., Stringfellow D.A., Kumar A., Stephens C.E. et al. Detection of inhibition of bovine viral diarrhea virus by aromatic cationic molecules. Antimicrob. Agents Chemother. 2003; 47(7): 2223-30.
  16. Buckwold V.E., Wilson R.J., Nalca A., Beer B.B., Voss T.G., Turpin J.A. et al. Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res. 2004; 61(1): 57-2.
  17. Mazzei M., Nieddu E., Miele M., Balbi A., Ferrone M., Fermeglia M. еt al. Activity of Mannich bases of 7-hydroxycoumarin against Flaviviridae. Bioorg. Med. Chem. 2008; 16(5): 2591-605.
  18. Giampieri M., Balbi A., Mazzei M., La Colla P., Ibba C., Loddo R. Antiviral activity of indole derivatives. Antiviral Res. 2009; 83(2): 179-85.
  19. Zhang N., Liu Z., Han Q., Chen J., Lou S., Qiu J. et al. Inhibition of bovine viral diarrhea virus in vitro by xanthohumol: comparisons with ribavirin and interferon-alpha and implications for the development of anti-hepatitis C virus agents. Eur. J. Pharm. Sci. 2009; 38(4): 332-40.
  20. Ibrahim M.M., Mazzei M., Delogu I., Szabó R., Sanna G., Loddo R. Activity of bis (7-hydroxycoumarin) Mannich bases against bovine viral diarrhoea virus. Antiviral Res. 2016; 134: 153-60.
  21. Chezal J.M., Paeshuyse J., Gaumet V., Canitrot D., Maisonial A., Lartigue C. et al. Synthesis and antiviral activity of an imidazo [1,2-a] pyrrolo [2,3-c] pyridine series against the bovine viral diarrhea virus. Eur. J. Med. Chem. 2010; 45(5): 2044-7.
  22. Paeshuyse J., Letellier C., Froeyen M., Dutartre H., Vrancken R., Canard B. et al. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase. Antiviral Res. 2009; 82(3): 141-7.
  23. Baginski S.G., Pevear D.C., Seipel M., Sun S.C., Benetatos C.A., Chunduru S.K. et al. Mechanism of action of a pestivirus antiviral compound. Proc. Natl. Acad. Sci. USA. 2000; 97(14): 7981-6.
  24. Manfredini S., Angusti A., Veronese A.C., Durini E., Vertuani S., Nalin F. et al. Hindered nucleoside analogs as antiflaviviridae agents. Pure Appl. Chem. 2004; 76: 1007-5.
  25. Pierra C., Amador A., Badaroux E., Storer R., Gosselin G. Synthesis of 2‘-Cmethylcytidine and 2‘-C-methyluridine derivatives modified in the 3‘-position as potential antiviral agents. Coll. Czech. Chem. Comm. 2006; 71: 991-1010.
  26. Angusti A., Manfredini S., Durini E., Ciliberti N., Vertuani S., Solaroli N. et al. Design, synthesis and anti flaviviridae activity of N(6)-, 5’,3’-O- and 5’,2’-O-substituted adenine nucleoside analogs. Chem. Pharm. Bull. (Tokyo). 2008; 56(4): 423-32.
  27. Finkielsztein L.M., Moltrasio G.Y., Caputto M.E., Castro E.F., Cavallaro L.V., Moglioni A.G. What is known about the antiviral agents active against bovine viral diarrhea virus (BVDV)? Curr. Med. Chem. 2010; 17(26): 2933-55.
  28. Giliberti G., Ibba C., Marongiu E., Loddo R., Tonelli M., Boido V. et al. Synergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase. Bioorg. Med. Chem. 2010; 18(16): 6055-8.
  29. Finkielsztein L.M., Castro E.F., Fabián L.E., Moltrasio G.Y., Campos R.H., Cavallaro L.V. et al. New 1-indanone thiosemicarbazone derivatives active against BVDV. Eur. J. Med. Chem. 2008; 43(8): 1767-3.
  30. Castro E.F., Fabian L.E., Caputto M.E., Gagey D., Finkielsztein L.M., Moltrasio G.Y. et al. Inhibition of bovine viral diarrhea virus RNA synthesis by thiosemicarbazone derived from 5,6-dimethoxy-1-indanone. J. Virol. 2011; 85: 5436-5.
  31. Tonelli M., Simone M., Tasso B., Novelli F., Boido V., Sparatore F. et al. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2 phenylbenzimidazole derivatives. Bioorg. Med. Chem. 2010; 18(8): 2937-3.
  32. Newcomer B.W., Marley M.S., Galik P.K., Walz P.H., Zhang Y., Riddell K.P. et al. Antiviral treatment of calves persistently infected with bovine viral diarrhoea virus. Antivir. Chem. Chemother. 2012; 22(4): 171-9.
  33. Newcomer B.W., Marley M.S., Galik P.K., Zhang Y., Riddell K.P., Boykin D.W. et al. Effect of treatment with a cationic antiviral compound on acute infection with bovine viral diarrhea virus. Can. J. Vet. Res. 2013; 77(3): 170-6.
  34. Newcomer B.W., Neill J.D., Marley M.S., Ridpath J.F., Givens M.D. Mutations induced in the NS5B gene of bovine viral diarrhea virus by antiviral treatment convey resistance to the compound. Virus Res. 2013; 96(1-2): 127-9.
  35. Givens M.D., Stringfellow D.A., Riddell K.P., Galik P.K., Carson R.L., Riddell M.G. et al. Normal calves produced after transfer of in vitro fertilized embryos cultured with an antiviral compound. Theriogenology. 2006; 65(2): 344-5.
  36. Givens M.D., Marley M.S., Riddell K.P., Galik P.K., Stringfellow D.A. Normal reproductive capacity of heifers that originated from in vitro fertilized embryos cultured with an antiviral compound. Anim. Reprod. Sci. 2009; 113(1-4): 283-6.
  37. Escuret V., Parvaz P., Hantz O., Petit M.A., Trepo C., Zoulim F. Study of the antiviral mechanism of action of ribavirin in the bovine viral diarrhea virus model. Gastroenterol. Clin. Biol. 2002; 26(6-7): 584-90. (in French)
  38. Yanagida K., Baba C., Baba M. Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha. Antiviral Res. 2004; 64(3): 195-201.
  39. Stuyver L.J., Lostia S., Patterson S.E., Clark J.L., Watanabe K.A., Otto M.J. et al. Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents. Antivir. Chem. Chemother. 2002; 13(6): 345-52.
  40. Mishra N., Rajukumar K., Kalaiyarasu S., Behera S.P., Nema R.K., Dubey S.C. Small interfering RNAs targeting viral structural envelope protein genes and the 5’-UTR inhibitreplication of bovine viral diarrhea virus in MDBK cells. Acta Virol. 2011; 55(3): 279-82.
  41. Lambeth L.S., Moore R.J., Muralitharan M.S., Doran T.J. Suppression of bovine viral diarrhea virus replication by small interfering RNA and short hairpin RNA-mediated RNA interference. Vet. Microbiol. 2007; 119(2-4): 132-43.
  42. Ni W., Hu S., Qiao J., Yu Y., Wang D., Tong Q. et al. Suppression of bovine viral diarrhea virus replication by single and dual short hairpin RNA-mediated RNA interference. Res. Vet. Sci. 2012; 93(1): 544-8.
  43. Ni W., Qiao J., Ma Q., Wang J., Wang D., Zhao X. et al. Development of sheep kidney cells with increased resistance to different subgenotypes of BVDV-1 by RNA interference. J. Virol. Methods. 2015; 218: 66-70.
  44. Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016; 4(7): 35-50.
  45. Fischer M.A., Smith J.L., Shum D., Stein D.A., Parkins C., Bhinder B. et al. Flaviviruses are sensitive to inhibition of thymidine synthesis. J. Virol. 2013; 87(17): 9411-9.
  46. Hoover S., Striker R. Thiopurines inhibit bovine viral diarrhea virus production in a thiopurine methyltransferase-dependentmanner. J. Gen. Virol. 2008; 89(Pt. 4): 1000-9.
  47. Koehler K.A., Lienhard G.E. 2-phenylethaneboronic acid, a possible transition-state analog for chymotrypsin. Biochemistry. 1971; 10(13): 2477-3.
  48. Bukhtiyarova M., Rizzo C.J., Kettner C.A., Korant B.D., Scarnati H.T., King R.W. Inhibition of the bovine viral diarrhea virus NS3 serine protease by a boron-modified peptidyl mimetic of its natural substrate. Antivir. Chem. Chemother. 2001; 12: 367-3.
  49. Иванов М.А., Иванов А.В., Красницкая И.А., Смирнова О.А., Карпенко И.Л., Беланов Е.Ф. и др. Новые фурано- и пирроло [2,3-D] пиримидиновые нуклеозиды и их 5-трифосфаты: синтез и биологические свойства. Биоорганическая химия. 2008; (5): 661-70
  50. Baharuddin A., Hassan A.A., Sheng G.C., Nasir S.B., Othman S., Yusof R. et al. Current approaches in antiviral drug discovery against the flaviviridae family. Curr. Pharm. Des. 2014; 20(21): 3428-44.
  51. Alonzi D.S., Dwek R.A., Butters T.D. Improved cellular inhibitors for glycoprotein processing alpha-glucosidases: biological characterization of alkyl- and arylalkyl-N-substituted deoxynojirimycins. Tetrahedron Asymmetry. 2009; 20: 897-1.
  52. Mehta A., Ouzounov S., Jordan R., Simsek E., Lu X., Moriarty R.M. et al. Imino sugars that are less toxic but more potent as antivirals, in vitro, compared with N-n-nonyl DNJ. Antivir. Chem. Chemother. 2002; 13(5): 299-4.
  53. Whitby K., Taylor D., Patel D., Ahmed P., Tyms A.S. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for thetreatment of hepatitis C. Antivir. Chem. Chemother. 2004; 15(3): 141-51.
  54. Durantel D., Branza-Nichita N., Carrouée-Durantel S., Butters T.D., Dwek R.A., Zitzmann N. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 2001; 75(19): 8987-8.
  55. Du Y., Ye H., Gill T., Wang L., Guo F., Cuconati A. et al. N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections. Bioorg. Med. Chem. Lett. 2013; 23(7): 2172-6.
  56. Poh M.K., Yip A., Zhang S., Priestle J.P., Ma N.L., Smit J.M. et al. A small molecule fusion inhibitor of dengue virus. Antiviral. Res. 2009; 84(3): 260-6.
  57. Yennamalli R., Subbarao N., Kampmann T., McGeary R.P., Young P.R., Kobe B. Identification of novel target sites and an inhibitor of the dengue virus E protein. J. Comput. Aided. Mol. Des. 2009; 23(6): 333-41.
  58. Griffin S.D., Beales L.P., Clarke D.S., Worsfold O., Evans S.D., Jaeger J. et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 2003; 535(1-3): 34-8.
  59. Harada T., Tautz N., Thiel H.J. E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies. J. Virol. 2000; 74(20): 9498-6.
  60. Griffin S.D.C., Harvey R., Clarke D.S., Barclay W.S., Harris M., Rowlands D.J. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J. Gen. Virol. 2004; 85(Pt. 2): 451-61.
  61. Foster T.L., Verow M., Wozniak A.L., Bentham M.J., Thompson J., Atkins E. et al. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatolodgy. 2011; 54(l): 79-90.
  62. Luscombe C.A., Huang Z., Murray M.G., Miller M., Wilkinson J., Ewart G.D. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res. 2010; 86(2): 144-3.
  63. Bastos J.C., Kohn L.K., Fantinatti-Garboggini F., Padilla M.A., Flores E.F., da Silva B.P. et al. Antiviral activity of Bacillus sp. isolated from the marine sponge Petromica citrina against bovine viral diarrhea virus, a surrogate model of the hepatitis C virus. Viruses. 2013; 5(5): 1219-30.
  64. Johnston A., Uren E., Johnstone D., Wu J. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies. Biologicals. 2003; 31(3): 213-1.
  65. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R. et al. The interferons: mechanisms of action and clinical applications. JAMA. 1991; 266(10): 1375-3.
  66. Глотова Т.И., Кунгурцева О.В., Глотов А.Г. Действие препаратов экзогенного интерферона на вирус вирусной диареи-болезни слизистых крупного рогатого скота. Аграрный вестник Урала. 2012; (5): 34-6
  67. Kohara J., Nishikura Y., Konnai S., Tajima M., Onuma M. Effects of interferon-tau on cattle persistently infected with bovine viral diarrhea virus. Jpn. J. Vet. Res. 2012; 60(2-3): 63-70.
  68. Peek S.F., Bonds M.D., Schaele P., Weber S., Friedrichs K., Schultz R.D. Evaluation of antiviral activity and toxicity of recombinant human interferon alfa-2a in calves persistently infected with type 1 bovine viral diarrhea virus. Am. J. Vet. Res. 2004; 65(6): 865-70.
  69. Iqbal M., Poole E., Goodbourn S., McCauley J.W. Role for bovine viral diarrhea virus Erns glycoprotein in the control of activation of beta interferon by double-stranded RNA.J. Virol. 2004; 78(1): 136-5.
  70. Ямковая Т.В., Глотова Т.И., Глотов А.Г., Семенова О.В., Ямковой В.И., Панин Л.Е. Активность препарата Виталанг-2 в отношении возбудителя вирусной диареи - болезни слизистых оболочек КРС. Ветеринария. 2014; (3): 10-4
  71. Song Q., Weng X.G., Cai D.J., Zhang W., Wang J.F. Forsythoside A Inhibits BVDV Replication via TRAF2-Dependent CD28-4-1BB Signaling in Bovine PBMCs. PLoS One. 2016; 11(9): e0162791.
  72. Passler T., Walz P.H. Bovine viral diarrhea virus infections in heterologous species. Anim. Health Res. Rev. 2010; 11(2):191-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Glotova T.I., Nikonova A.A., Glotov A.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies